LXRX · Lexicon Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$1.79
-0.03 (-1.65%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$796.97M
Shares
445.23M
Volume · Nov 13
1.89M
Avg daily vol (3M)
2.62M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Lexicon Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Lexicon Pharmaceuticals, Inc. (LXRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2026 Earnings Call Transcript
Confident tone
Sonata HCM Phase 3 readout
Regulatory submission preparation and delay
ZENQISTA NDA resubmission
Revenue
$11.25M
▼ 20.7% YoY Diluted EPS
$-0.03
Gross margin
99.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Lexicon Pharmaceuticals, Inc. (LXRX) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Lexicon Pharmaceuticals, Inc. (LXRX) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Confident tone
Zynquista (sotagliflozin) NDA Resubmission
Sotagliflozin Mechanism and HCM Differentiation
Forward-Looking Risks / Regulatory Dependence
Revenue
$692,000
▼ 97.6% YoY Diluted EPS
$-0.07
▼ 800% YoY Gross margin
94.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Lexicon Pharmaceuticals, Inc. (LXRX) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Confident tone
Sodagliflozin in HCM (SONATA Phase 3)
LX9851 / Novo Nordisk collaboration in obesity
Financial position & operational discipline
Revenue
$21.10M
▲ 1572.1% YoY Diluted EPS
$0.00
Gross margin
99.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Confident tone
Sodagliflozin in HCM (Sonata Phase 3)
Mechanism of action / SGLT1 differentiation
LX9851 obesity program with Novo Nordisk
Revenue
$5.49M*
▼ 79.3% YoY Gross margin
96.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript
Positive tone
SONATA Phase III trial in HCM
Zynquista FDA path forward in type 1 diabetes
Pilavapadin (DPNP) Phase III readiness and partnering
Revenue
$14.18M
▲ 710.4% YoY Diluted EPS
$-0.04
Gross margin
99.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript
Confident tone
Sotagliflozin (SOTA) in HCM (Sonata Phase 3)
Pilavapidin in neuropathic pain (DPNP)
Competitive landscape / NAV inhibitors in pain
Revenue
$28.87M
▲ 1652.6% YoY Diluted EPS
$0.01
Gross margin
99.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript
Confident tone
Pilavapadin Phase 3 path for DPNP
Sotagliflozin SONATA HCM pivotal study
Clinical trial enrollment environment
Revenue
$1.26M
▲ 11.7% YoY Diluted EPS
$-0.07
Gross margin
97.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call
Revenue
$26.55M*
▲ 3688% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-22
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Balanced tone
Sotagliflozin pipeline: SONATA HCM Phase 3
LX9211 Phase 2b in diabetic peripheral neuropathic pain
ZYNQUISTA FDA AdCom and PDUFA decision
Revenue
$1.75M
▲ 980.2% YoY Diluted EPS
$-0.18
Gross margin
95.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
Positive tone
Zynquista NDA resubmission and Type 1 diabetes launch
INPEFA commercial performance in heart failure
Sotagliflozin pipeline expansion (HCM, neuropathic pain)
Revenue
$1.65M
▲ 419.6% YoY Diluted EPS
$-0.17
Gross margin
89.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-05-03
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2023 Earnings Call
Revenue
$701,000*
Gross margin
90.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q1
2024-05-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
Positive tone
Zynquista Type 1 Diabetes NDA Resubmission
INPEFA Heart Failure Commercial Launch
Sotagliflozin Label Expansion into HCM
Revenue
$1.13M
▲ 4608.3% YoY Diluted EPS
$-0.20
Gross margin
97.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-08
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2023 Earnings Call Transcript
Revenue
$162,000
▲ 315.4% YoY Diluted EPS
$-0.21
Gross margin
95.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript
Revenue
$317,000
▲ 805.7% YoY Diluted EPS
$-0.22
Gross margin
97.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2023 Earnings Call Transcript
Revenue
$24,000
Diluted EPS
$-0.17
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript
Revenue
$39,000
▲ 69.6% YoY Diluted EPS
$-0.13
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2022 Earnings Call Transcript
Revenue
$35,000
▼ 85% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2021 Earnings Call Transcript
Revenue
$14,000*
▼ 93% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2021 Earnings Call Transcript
Revenue
$23,000
▼ 99.7% YoY Diluted EPS
$-0.16
▼ 122.5% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-30
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2021 Earnings Call Transcript
Revenue
$234,000
▼ 97.4% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2021 Earnings Call Transcript
Revenue
$27,000
▼ 99.7% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2020 Earnings Call Transcript
Revenue
$199,000*
▼ 97.7% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2020 Earnings Call Transcript
Revenue
$6.63M
▼ 97.7% YoY Diluted EPS
$0.71
▼ 63.6% YoY Gross margin
90.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2020 Earnings Call Transcript
Revenue
$9.16M
▼ 5.4% YoY Gross margin
92.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-27
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2020 Earnings Call Transcript
Revenue
$8.00M
▼ 13.2% YoY Gross margin
92.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2019 Earnings Call
Revenue
$8.73M
▼ 48.9% YoY Diluted EPS
$-0.48
Gross margin
91.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 webcasts
Key facts
CIK
1062822
CUSIP
528872302
13F (30d)
122 filings
108 filers
Visit website
Investor relations